IMPOWER150
Regimen
- Experimental
- atezolizumab + bevacizumab + carbo + paclitaxel
- Control
- bev + carbo + paclitaxel
Population
1L non-sq NSCLC incl. EGFR/ALK after TKI failure
Key finding
ABCP vs BCP PFS HR 0.62 (0.52-0.74); mOS 19.2 vs 14.7 mo HR 0.78 (0.64-0.96)
Source: PMID 29863955
Timeline
- Enrollment start: 2015-03-31 📎
Guideline citations
- NCCN NSCLC Version 5.2026 (p.174)
- CSCO NSCLC 2025 ⚠️ OCR source